Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10184584

Purchasing silicone.

T Pryce
View original source ↗Export metadata ↓

Abstract

Now that CE-marking of medical devices is in force, device manufacturers need to be able to document that they employ the correct materials and components for a particular application. To do this they need to understand exactly what they are purchasing and show that their suppliers possess the necessary product range, technical expertise, and, most importantly, the quality procedures required to assure product integrity. This article sets out some basic definitions of terminology relating to material specification and testing of silicone products.

Explore related subjects

Device ApprovalEquipment and SuppliesHumansMaterials TestingSiliconesTerminology as TopicUnited StatesUnited States Food and Drug AdministrationJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Pryce. 1996. Purchasing silicone.. https://pubmed.ncbi.nlm.nih.gov/10184584/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Medical devices; immunology and microbiology devices; classification of fecal calprotectin immunological test systems. Final rule.

The Food and Drug Administration (FDA) is classifying fecal calprotectin immunological test systems into class II (special controls). The special control that will apply to these devices is the guidance document entitled, "Class II Special Controls Guidance Document: Fecal Calprotectin Immunological Test Systems." The agency is classifying these devices into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of these devices. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document that will serve as the special control for these devices.

Device Approval↗
PubMed2006

Medical devices; exception from general requirements for informed consent. Interim final rule.

The Food and Drug Administration (FDA) is issuing this interim final rule to amend its regulations to establish a new exception from the general requirements for informed consent, to permit the use of investigational in vitro diagnostic devices to identify chemical, biological, radiological, or nuclear agents without informed consent in certain circumstances. The agency is taking this action because it is concerned that, during a potential terrorism event or other potential public health emergency, delaying the testing of specimens to obtain informed consent may threaten the life of the subject. In many instances, there may also be others who have been exposed to, or who may be at risk of exposure to, a dangerous chemical, biological, radiological, or nuclear agent, thus necessitating identification of the agent as soon as possible. FDA is creating this exception to help ensure that individuals who may have been exposed to a chemical, biological, radiological, or nuclear agent are able to benefit from the timely use of the most appropriate diagnostic devices, including those that are investigational.

Device Approval↗